Grandvuillemin Aurélie, Jolimoy Geneviève, Authier François, Dautriche Anne, Duhoux Fabienne, Sgro Catherine
Centre Régional de Pharmacovigilance, Pôle des Pathologies Lourdes et Vigilances, Dijon.
Presse Med. 2006 Dec;35(12 Pt 1):1842-4. doi: 10.1016/s0755-4982(06)74913-2.
Tramadol has been approved in France since 1994 for the treatment of moderate to severe pain. The most commonly reported adverse effects involve the central nervous system and gastrointestinal tract. To our knowledge, hypoglycemia has not previously been reported.
We report 2 cases of hypoglycemia related to tramadol, one in a nondiabetic 88-year-old woman, and the other in a diabetic 8-year-old girl. Hypoglycemia resolved after tramadol discontinuation.
The French Pharmacovigilance (Adverse Drug Reports) database includes several cases of hypoglycemia in patients receiving tramadol. Reports from the literature of dextropropoxyphene-induced hypoglycemia and a pharmacological study of tramadol in rats suggest that the micro opioid receptor is the principal target involved in this hypoglycemic mechanism.
曲马多自1994年起在法国被批准用于治疗中度至重度疼痛。最常报告的不良反应涉及中枢神经系统和胃肠道。据我们所知,此前尚未有低血糖的报告。
我们报告2例与曲马多相关的低血糖病例,1例发生在一名88岁非糖尿病女性身上,另1例发生在一名8岁糖尿病女孩身上。停用曲马多后低血糖症状缓解。
法国药物警戒(药品不良反应报告)数据库包含数例接受曲马多治疗患者出现低血糖的病例。右丙氧芬致低血糖的文献报道以及曲马多在大鼠身上的药理学研究表明,微阿片受体是这种低血糖机制的主要作用靶点。